Chemours Q4 Adj EPS $0.31 Beats $0.25 Estimate, Sales $1.36B Beat $1.32B Estimate
Portfolio Pulse from Benzinga Newsdesk
Chemours (NYSE:CC) reported Q4 adjusted earnings of $0.31 per share, surpassing the consensus estimate of $0.25 by 24%. Quarterly sales reached $1.36 billion, exceeding the $1.32 billion estimate by 3.11% and marking a 1.72% increase from the previous year.
March 27, 2024 | 9:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Chemours reported Q4 adjusted EPS of $0.31, beating estimates by 24%, and sales of $1.36B, exceeding expectations by 3.11%.
Chemours' Q4 earnings and sales not only surpassed analyst expectations but also showed growth compared to the same period last year. This positive performance, especially in beating both earnings and sales estimates, is likely to instill investor confidence and could lead to a short-term uptick in the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100